CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control

References

• Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol 2013; 34:50-8; PMID:23017731; http://dx.doi.org/10.1016/j.it.2012.08.009
   PubMed Web of Science ®Google Scholar
• Mattner J, Debord KL, Ismail N, Goff RD, Cantu 3rd C, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434:525-9; PMID:15791258; http://dx.doi.org/10.1038/nature03408
   PubMed Web of Science ®Google Scholar
• Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 2003; 198:173-81; PMID:12847141; http://dx.doi.org/10.1084/jem.20030446
   PubMed Web of Science ®Google Scholar
• Cullen R, Germanov E, Shimaoka T, Johnston B. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol 2009; 183:5807-15; PMID:19812206; http://dx.doi.org/10.4049/jimmunol.0803520
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, Clattenburg DR, Slauenwhite D, Lobert L, Johnston B. Natural killer T cell activation overcomes immunosuppression to enhance clearance of post-surgical breast cancer metastasis in mice. Oncoimmunology 2015; 4:e995562; PMID:25949924; http://dx.doi.org/10.1080/2162402X.2014.995562
   PubMedGoogle Scholar
• Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci U S A 1998; 95:5690-3; PMID:9576945; http://dx.doi.org/10.1073/pnas.95.10.5690
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Rovero S, Forni G, Smyth MJ. α-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci U S A 2003; 100:9464-9; PMID:12867593; http://dx.doi.org/10.1073/pnas.1630663100
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, Slauenwhite D, Johnston B. Reconstitution models to evaluate natural killer T cell function in tumor control. Immunol Cell Biol 2016; 94:90-100; PMID:26095148; http://dx.doi.org/10.1038/icb.2015.67
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191:661-8; PMID:10684858; http://dx.doi.org/10.1084/jem.191.4.661
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166:6012-8; PMID:11342617; http://dx.doi.org/10.4049/jimmunol.166.10.6012
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI. Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002; 99:1259-66; PMID:11830474; http://dx.doi.org/10.1182/blood.V99.4.1259
   PubMed Web of Science ®Google Scholar
• Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I et al. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182:2492-501; PMID:19201905; http://dx.doi.org/10.4049/jimmunol.0800126
   PubMed Web of Science ®Google Scholar
• Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997; 278:1626-9; PMID:9374463; http://dx.doi.org/10.1126/science.278.5343.1626
   PubMed Web of Science ®Google Scholar
• Matsuda JL, Naidenko O V, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192:741-54; PMID:10974039; http://dx.doi.org/10.1084/jem.192.5.741
   PubMed Web of Science ®Google Scholar
• Tomura M, Yu WG, Ahn HJ, Yamashita M, Yang YF, Ono S, Hamaoka T, Kawano T, Taniguchi M, Koezuka Y et al. A novel function of Vα14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 1999; 163:93-101; PMID:10384104
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198:267-79; PMID:12874260; http://dx.doi.org/10.1084/jem.20030324
   PubMed Web of Science ®Google Scholar
• Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189:1121-8; PMID:10190903; http://dx.doi.org/10.1084/jem.189.7.1121
   PubMed Web of Science ®Google Scholar
• Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol 2011; 186:3401-9; PMID:21321106; http://dx.doi.org/10.4049/jimmunol.1000328
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur J Immunol 2001; 31:1720-7; PMID:11385616; http://dx.doi.org/10.1002/1521-4141(200106)31:6%3c1720::AID-IMMU1720%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171:5140-7; PMID:14607913; http://dx.doi.org/10.4049/jimmunol.171.10.5140
   PubMed Web of Science ®Google Scholar
• Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ. Role of γδ T cells in α-galactosylceramide-mediated immunity. J Immunol 2012; 188:3928-39; PMID:22412194; http://dx.doi.org/10.4049/jimmunol.1103582
   PubMed Web of Science ®Google Scholar
• Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: Shared and differential chemokine receptor expression among Vα24+Vβ11+ NKT cell subsets with distinct cytokine-producing capacity. Blood 2002; 100:11-6; PMID:12070001; http://dx.doi.org/10.1182/blood-2001-12-0196
   PubMed Web of Science ®Google Scholar
• Slauenwhite D, Johnston B. Regulation of NKT Cell Localization in Homeostasis and Infection. Front Immunol 2015; 6:255; PMID:26074921; http://dx.doi.org/10.3389/fimmu.2015.00255
   PubMed Web of Science ®Google Scholar
• Johnston B, Kim CH, Soler D, Emoto M, Butcher EC. Differential chemokine responses and homing patterns of murine TCR αβ NKT cell subsets. J Immunol 2003; 171:2960-9; PMID:12960320; http://dx.doi.org/10.4049/jimmunol.171.6.2960
   PubMed Web of Science ®Google Scholar
• Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ, Dustin ML, Littman DR. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005; 3:0650-61; PMID:15799695; http://dx.doi.org/10.1371/journal.pbio.0030113
   Web of Science ®Google Scholar
• Germanov E, Veinotte L, Cullen R, Chamberlain E, Butcher EC, Johnston B. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J Immunol 2008; 181:81-91; PMID:18566372; http://dx.doi.org/10.4049/jimmunol.181.1.81
   PubMed Web of Science ®Google Scholar
• Shimaoka T, Seino K, Kume N, Minami M, Nishime C, Suematsu M, Kita T, Taniguchi M, Matsushima K, Yonehara S. Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. J Immunol 2007; 179:8172-9; PMID:18056360; http://dx.doi.org/10.4049/jimmunol.179.12.8172
   PubMed Web of Science ®Google Scholar
• Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000; 1:298-304; PMID:11017100; http://dx.doi.org/10.1038/79738
   PubMed Web of Science ®Google Scholar
• Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P, Andrew DP, Wu L, Briskin M. Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001; 166:5145-54; PMID:11290797; http://dx.doi.org/10.4049/jimmunol.166.8.5145
   PubMed Web of Science ®Google Scholar
• van der Voort R, Verweij V, de Witte TM, Lasonder E, Adema GJ, Dolstra H. An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells. J Leukoc Biol 2010; 87:1029-39; PMID:20181724; http://dx.doi.org/10.1189/jlb.0709482
   PubMed Web of Science ®Google Scholar
• Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-γ and TNF-α and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004; 172:6362-72; PMID:15128827; http://dx.doi.org/10.4049/jimmunol.172.10.6362
   PubMed Web of Science ®Google Scholar
• Tohyama M, Sayama K, Komatsuzawa H, Hanakawa Y, Shirakata Y, Dai X, Yang L, Tokumaru S, Nagai H, Hirakawa S et al. CXCL16 is a novel mediator of the innate immunity of epidermal keratinocytes. Int Immunol 2007; 19:1095-102; PMID:17855433; http://dx.doi.org/10.1093/intimm/dxm083
   PubMed Web of Science ®Google Scholar
• van Lieshout AWT, van der Voort R, Toonen LWJ, van Helden SFG, Figdor CG, van Riel PLCM, Radstake TRDJ, Adema GJ. Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1036-43; PMID:18628285; http://dx.doi.org/10.1136/ard.2007.086611
   PubMed Web of Science ®Google Scholar
• Paust S, Gill HS, Wang B-Z, Flynn MP, Moseman EA, Senman B, Szczepanik M, Telenti A, Askenase PW, Compans RW et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010; 11:1127-35; PMID:20972432; http://dx.doi.org/10.1038/ni.1953
   PubMed Web of Science ®Google Scholar
• Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999; 163:2387-91; PMID:10452972
   PubMed Web of Science ®Google Scholar
• Wang H, Feng D, Park O, Yin S, Gao B. Invariant NKT cell activation induces neutrophil accumulation and hepatitis: Opposite regulation by IL-4 and IFN-γ. Hepatology 2013; 58:1474-85; PMID:23686838; http://dx.doi.org/10.1002/hep.26471
   PubMed Web of Science ®Google Scholar
• Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y. Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008; 57:337-45; PMID:17690880; http://dx.doi.org/10.1007/s00262-007-0373-5
   PubMed Web of Science ®Google Scholar
• Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009; 100:1092-8; PMID:19302288; http://dx.doi.org/10.1111/j.1349-7006.2009.01135.x
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011; 138:255-65; PMID:21185787; http://dx.doi.org/10.1016/j.clim.2010.11.014
   PubMed Web of Science ®Google Scholar
• Arora P, Baena A, Yu KA, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreño LJ, Venkataswamy MM, Kim J et al. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 2014; 40:105-16; PMID:24412610; http://dx.doi.org/10.1016/j.immuni.2013.12.004
   PubMed Web of Science ®Google Scholar
• Slauenwhite D, Gebremeskel S, Doucette CD, Hoskin DW, Johnston B. Regulation of Cytokine Polarization and T Cell Recruitment to Inflamed Paws in Mouse Collagen-Induced Arthritis by the Chemokine Receptor CXCR6. Arthritis Rheumatol 2014; 66:3001-12; PMID:25132679; http://dx.doi.org/10.1002/art.38816
   PubMed Web of Science ®Google Scholar
• Fukumoto N, Shimaoka T, Fujimura H, Sakoda S, Tanaka M, Kita T, Yonehara S. Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 2004; 173:1620-7; PMID:15265890; http://dx.doi.org/10.4049/jimmunol.173.3.1620
   PubMed Web of Science ®Google Scholar
• Fahy OL, Townley SL, McColl SR. CXCL16 regulates cell-mediated immunity to Salmonella enterica serovar enteritidis via promotion of γ interferon production. Infect Immun 2006; 74:6885-94; PMID:16982830; http://dx.doi.org/10.1128/IAI.01065-06
   PubMed Web of Science ®Google Scholar
• Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4:1230-7; PMID:14578883; http://dx.doi.org/10.1038/ni1002
   PubMed Web of Science ®Google Scholar
• Jiang X, Shimaoka T, Kojo S, Harada M, Watarai H, Wakao H, Ohkohchi N, Yonehara S, Taniguchi M, Seino K. Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 2005; 175:2051-5; PMID:16081769; http://dx.doi.org/10.4049/jimmunol.175.4.2051
   PubMed Web of Science ®Google Scholar
• Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt L A, McKenzie BS, Berzins SP, Smyth MJ, Godfrey DI. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4−NK1.1− NKT cell population. Proc Natl Acad Sci U S A 2008; 105:11287-92; PMID:18685112; http://dx.doi.org/10.1073/pnas.0801631105
   PubMed Web of Science ®Google Scholar
• Dutta T, Spence A, Lampson LA. Robust ability of IFN-γ to upregulate class II MHC antigen expression in tumor bearing rat brains. J Neurooncol 2003; 64:31-44; PMID:12952284
   PubMed Web of Science ®Google Scholar
• Svane IM, Engel AM, Nielsen M, Werdelin O. Interferon-γ-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas. Scand J Immunol 1997; 46:379-87; PMID:9350289; http://dx.doi.org/10.1046/j.1365-3083.1997.d01-141.x
   PubMed Web of Science ®Google Scholar
• Bradley LM, Dalton DK, Croft M. A direct role for IFN-γ in regulation of Th1 cell development. J Immunol 1996; 157:1350-8; PMID:8759714
   PubMed Web of Science ®Google Scholar
• Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 1993; 259:1739-42; PMID:8456300; http://dx.doi.org/10.1126/science.8456300
   PubMed Web of Science ®Google Scholar
• Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-γ for Th1 priming. Nat Immunol 2004; 5:1260-5; PMID:15531883; http://dx.doi.org/10.1038/ni1138
   PubMed Web of Science ®Google Scholar
• Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996; 272:719-22; PMID:8614832; http://dx.doi.org/10.1126/science.272.5262.719
   PubMed Web of Science ®Google Scholar
• Platanias LC, Uddin S, Bruno E, Korkmaz M, Ahmad S, Alsayed Y, Van Den Berg D, Druker BJ, Wickrema A, Hoffman R. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp Hematol 1999; 27:1315-21; PMID:10428508; http://dx.doi.org/10.1016/S0301-472X(99)00060-0
   PubMed Web of Science ®Google Scholar
• Hobeika AC, Etienne W, Torres BA, Johnson HM, Subramaniam PS. IFN-γ induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res 1999; 19:1351-61; PMID:10638704; http://dx.doi.org/10.1089/107999099312812
   PubMed Web of Science ®Google Scholar
• Beatty G, Paterson Y. IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ. J Immunol 2001; 166:2276-82; PMID:11160282; http://dx.doi.org/10.4049/jimmunol.166.4.2276
   PubMed Web of Science ®Google Scholar
• Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L et al. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9:25-34; PMID:9697833; http://dx.doi.org/10.1016/S1074-7613(00)80585-3
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Lindner DJ, Liu Y-F, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49; PMID:12766484; http://dx.doi.org/10.1023/A:1023668705040
   PubMed Web of Science ®Google Scholar
• Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol 2013; 14:1146-54; PMID:24097110; http://dx.doi.org/10.1038/ni.2731
   PubMed Web of Science ®Google Scholar
• Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181:3099-107; PMID:18713980; http://dx.doi.org/10.4049/jimmunol.181.5.3099
   PubMed Web of Science ®Google Scholar
• Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007; 67:4725-31; PMID:17510400; http://dx.doi.org/10.1158/0008-5472.CAN-06-3424
   PubMed Web of Science ®Google Scholar
• Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund L-T et al. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer 2015; 15:441; PMID:26021984; http://dx.doi.org/10.1186/s12885-015-1446-z
   PubMed Web of Science ®Google Scholar
• Kee J-Y, Ito A, Hojo S, Hashimoto I, Igarashi Y, Tsukada K, Irimura T, Shibahara N, Nakayama T, Yoshie O et al. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol Rep 2013; 29:975-82; PMID:23242131; http://dx.doi.org/10.3892or.2012.2185
   PubMed Web of Science ®Google Scholar
• Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermüller N, Doberstein K, Koziolek M, Fritzsche F, Johannsen M et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 2009; 45:478-89; PMID:19070478; http://dx.doi.org/10.1016/j.ejca.2008.10.023
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Y, Wang J, Koch AE, Zhang J, Taichman RS. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 2008; 68:10367-76; PMID:19074906; http://dx.doi.org/10.1158/0008-5472.CAN-08-2780
   PubMed Web of Science ®Google Scholar
• Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 2009; 4:e6695; PMID:19690611; http://dx.doi.org/10.1371/journal.pone.0006695
   PubMed Web of Science ®Google Scholar
• Gooden MJM, Wiersma VR, Boerma A, Leffers N, Boezen HM, ten Hoor KA, Hollema H, Walenkamp AME, Daemen T, Nijman HW et al. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. Br J Cancer 2014; 110:1535-44; PMID:24518602; http://dx.doi.org/10.1038/bjc.2014.55
   PubMed Web of Science ®Google Scholar
• Matsushita K, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K, Inoue Y, Kusunoki M. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol 2012; 19:518-27; PMID:21845497; http://dx.doi.org/10.1245/s10434-011-1993-8
   PubMed Web of Science ®Google Scholar
• Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J et al. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br J Cancer 2015; 112:1895-903; PMID:26010411; http://dx.doi.org/10.1038/bjc.2015.163
   PubMed Web of Science ®Google Scholar
• Gangemi R, Amaro A, Gino A, Barisione G, Fabbi M, Pfeffer U, Brizzolara A, Queirolo P, Salvi S, Boccardo S et al. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell Melanoma Res 2014; 27:1138-48; PMID:25124714; http://dx.doi.org/10.1111/pcmr.12306
   PubMed Web of Science ®Google Scholar
• Han EC, Lee J, Ryu SW, Choi C. Tumor-conditioned Gr-1+CD11b+ myeloid cells induce angiogenesis through the synergistic action of CCL2 and CXCL16 in vitro. Biochem Biophys Res Commun 2014; 443:1218-25; PMID:24388986; http://dx.doi.org/10.1016/j.bbrc.2013.12.117
   PubMed Web of Science ®Google Scholar
• Isozaki T, Arbab AS, Haas CS, Amin MA, Arendt MD, Koch AE, Ruth JH. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: Studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum 2013; 65:1736-46; PMID:23633118; http://dx.doi.org/10.1002/art.37981
   PubMed Web of Science ®Google Scholar
• Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110:793-800; PMID:12235110; http://dx.doi.org/10.1172/JCI0215832
   PubMed Web of Science ®Google Scholar
• Wen X, Rao P, Carreño LJ, Kim S, Lawrenczyk A, Porcelli SA, Cresswell P, Yuan W. Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc Natl Acad Sci U S A 2013; 110:2963-8; PMID:23382238; http://dx.doi.org/10.1073/pnas.1300200110
   PubMed Web of Science ®Google Scholar
• Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278:1623-6; PMID:9374462; http://dx.doi.org/10.1126/science.278.5343.1623
   PubMed Web of Science ®Google Scholar
• Unutmaz D, Xiang W, Sunshine MJ, Campbell J, Butcher E, Littman DR. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved Between Human and Mouse. J Immunol 2000; 165:3284-92; PMID:10975845; http://dx.doi.org/10.4049/jimmunol.165.6.3284
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, Levatte T, Liwski RS, Johnston B, Bezuhly M. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer 2015; 136:234-40; PMID:24798403; http://dx.doi.org/10.1002/ijc.28947
   PubMedGoogle Scholar